Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

• Published in: Annals of oncology Vol. 29; no. 4; pp. 1004 - 1009
• Main Authors: Tahara, M., Kiyota, N., Yokota, T., Hasegawa, Y., Muro, K., Takahashi, S., Onoe, T., Homma, A., Taguchi, J., Suzuki, M., Minato, K., Yane, K., Ueda, S., Hara, H., Saijo, K., Yamanaka, T.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.04.2018; Oxford University Press
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; carboplatin; Carboplatin - administration & dosage; cetuximab; Cetuximab - administration & dosage; Female; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - pathology; Humans; Male; Middle Aged; Neoplasm Metastasis; paclitaxel; Paclitaxel - administration & dosage; Recurrence; Squamous Cell Carcinoma of Head and Neck - drug therapy; Squamous Cell Carcinoma of Head and Neck - pathology; squamous cell carcinoma of the head and neck; paclitaxel; cetuximab; squamous cell carcinoma of the head and neck; carboplatin
• ISSN: 0923-7534; 1569-8041; 1569-8041
• DOI: 10.1093/annonc/mdy040

The standard of care for first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) is combination treatment with platinum, 5-FU and cetuximab (PFE). However, this regimen requires hospitalization to ensure proper hydration and continuous infusion of...